Cirrus Therapeutics的动态

?? We're excited to share the next 3 winners of RoosterBio's Development Award and their proposed work in "Novel #Exosome Analytical Methods or Potency Models.” Congratulations all! We eagerly look forward to seeing where this work progresses in time: 1?? Granular Hydrogels for The Controlled Delivery of MSC-Derived Immunomodulatory and Angiogenic Extracellular Vesicles to Enhance Bone Tissue Regeneration — Dr. Nicole Friend, PhD; Dr. Kristi Anseth 2?? Transcriptome Profile of Cells and Exosomes Between iPSC-Derived iMSCs and Tissue-Specific Primary MSCs — Associate Professor Zhen Ma 3?? Therapeutic Efficacy of Umbilical Cord Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Experimental Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis — Ishmael (Mikee) Inocencio, PhD Learn more about this award: https://lnkd.in/egRVvzeK #extracellularvesicles #exosomes #tissueregeneration #celltherapy #imsc #ipsc #hydrogels #regenerativemedicine #advancedtherapies

MedChemAdvent 21. ?????????????????????? (18??) (brand name Flyrcado) Flurpiridaz is a cyclotron-produced radioactive diagnostic agent for use with positron emission tomography (PET) myocardial perfusion imaging (MPI) to evaluate for myocardial ischemia and infarction. It is a first-of-its-kind imaging tracer for PET scans that helps assess the perfusion of heart muscle cells and gives a clearer picture of blocked arteries in the heart and any damage to cardiac tissue. Flurpiridaz was discovered by Lantheus (formerly known as Bristol-Myers Squibb Medical Imaging) and GE HealthCare did further development. The compound is a Mitochondrial Complex I (MC-I) inhibitor. It demonstrates?rapid uptake by cardiomyocytes with high first-pass extraction fraction by the heart and slow washout due to high specificity for and potent binding to MC-1. During the discovery of various pyridazinone analogs,?a structure-activity relationship (SAR) assessment indicated a preference for the fluorine label to be incorporated on an alkyl side chain rather than directly on the heterocyclic moiety. See the paper on Flurpiridaz discovery here: https://lnkd.in/e2JVeggu ???? ?????????? ???????? ???????? ???? 2024 ???????????? ????????????, ???? ?????????? ???????? ???? ???????????? ???????? ???????? ?????????????????? ???????? ???????? ???????? ???????????????? ???? ?????? ?????? ???? 2024. ???????? ?????? ?????????? ?????????????????? ???? ?????????????????? ?????? ???? ???????? ???? ?????? ??????????????????????????. ??????????! #MedChemAdvent #DrugDiscovery #MedicinalChemistry #FDA #Flurpiridaz #PET #Fluorine

New article is online ?? ???? "Inositol Restores Appropriate Steroidogenesis in PCOS Ovaries Both in Vitro and in Vivo Experimental Mouse Models". In this paper we demonstrated how "myo-Inositol exerts priceless regulatory activities upon ovary steroidogenesis and has been shown to efficiently rescue PCOS features by upregulating Cyp19a1 (aromatase) and Fshr levels while downregulating androgen excesses produced from Theca cells". Thanks to Mariano Bizzarri, Vittorio Unfer MD, Valeria Fedeli, Noemi Monti, Antonio Simone Laganà, Rita Canipari, Alessandro Querqui and @MDPIOpenAccess for this fruitful collaboration! Lo.Li.Pharma srl #inositols #PCOS #steroidogenesis #ovary #research #appliedscience

Reversing the surface charge of exosomes to improve their drug delivery potential: in their latest study, Ambika Goel Bajpayee at Northeastern University and collaborators engineered charge-reversed cationic exosomes for mRNA delivery by incorporating cartilage-targeting arginine-rich cationic motifs into the exosome bilayer, utilizing buffer pH as a switch to reverse the charge https://lnkd.in/egfAjVu4 Positively charged exosomes penetrated the full thickness of early-stage arthritic human cartilage by forming weak and reversible bonds with glycosaminoglycans , enabling efficient delivery of encapsulated eGFP-mRNA to chondrocytes in deeper tissue layers, a capability not observed with unmodified negatively charged exosomes. An article also authored by @Chenzhen Zhang, Tanvi Pathrikar, Helna M. Baby, Jun Li, Hengli Zhang, Andrew Selvadoss, Arina Ovchinnikova, Andreia Ionescu, SUSAN Chubinskaya and Rachel E. Miller #extracellularvesicles #exosomes #bioengineering #drugdelivery #nanomedicine #Vesiculab

?? Excited to initiate a research alliance with Navigo Proteins GmbH to establish novel and potentially much safer radioimmunoconjugates using pre-targeting strategies. ?? ?? The agreement brings together Navigo's Affilin? platform capable of providing highly specific targeted radiotheranostics with VERAXA’s proprietary click chemistry platform and conjugation expertise. ?? Pre-targeting strategies rely on separate injection of a tumor-targeting agent and subsequent delivery of a radioactive payload. The fact that our trans-cyclooctene (TCO)-based bioorthogonal click chemistry technology features one of the fastest reactions on the market may have special significance in the pre-targeting setting. ???? Using such a two-component system has the potential to enhance the targeting of cancer cells by delivering targeted radiation directly to the tumor, while minimizing the exposure of healthy tissues to radiation. ?? Meet VERAXA's CEO Christoph Antz and CBO Heinz Schwer, PhD, MBA during the J.P. Morgan Healthcare Week in San Francisco early 2025 to learn more about additional collaboration and investment opportunities. #ClickChemistry #radiopharmaceuticals #RICs #theranostics #precisiontargeting #precisionmedicine

INSIHGT is a new method for enhancing the depth penetration of antibodies and other macromolecular complexes for more homogenous labeling, paving the way for more impactful #SpatialBiology experiments in centimeter-scale tissue. This method works in two parts, first formaldehyde-fixed tissue is incubated with antibody and a weakly coordinated superchaotrope (WCS) to inhibit antibody-antigen interactions, allowing for even diffusion in the tissue. Second, the activity of the WCS is nullified by host-guest reactions with added macrocyclic compounds, restoring antibody activity. Click to check out the #OpenAccess article in Nature Communications: https://lnkd.in/ejv7aBE3 #Microscopy #Imaging

Researchers at Adaptimmune conduct extensive pre- and post-treatment tissue profiling in their clinical trials to understand the effectiveness of their cell-based therapies. In this clip from our recent webinar, Adaptimmune researchers explain how they used Ultivue’s InSituPlex? multiplex immunofluorescence (mIF) technology to select discrete regions of interest within biopsy samples for comparative transcriptomic analysis between treatment responders and non-responders. Watch the full webinar to learn what they found: https://hubs.ly/Q02N61Hs0 #SpatialBiology #Multiplex #mIF #ImmuneProfiling #ImmunoOncology #ImageAnalysis #TumorMicroenvironment #Biomarkers #BiomarkerDiscovery #InSituPlex #OmniVUE

???????????????????? ???????????????? ???? ?????????????????? ???????????? ?????????????? ????????????????????????? ???? Link in the first comment! ?? How can ???????????????????????? help restore vision in cases of retinal degeneration? Qi Lu, Anna Wright & Pan Zhuo-Hua, from Wayne State University, studied the effects of AAV dose on retinal ganglion cells (RGCs) and efficacy of optogenetic vision restoration. This preclinical study, published in ???????? ??????????????, provides important insights into potential therapies to restore vision in patients affected by blindness. We’re proud that Striatech’s ???????????????? ????????????? played a role in this cutting-edge research, enabling precise measurements of visual function after restoring vision. ?? Curious to learn more? Read our latest blog article to explore the study and its implications for optogenetic vision restoration. #Optogenetics #VisionRestoration #GeneTherapy #Striatech #InnovationInResearch

At?VitroScreen ?we are excited to announce the publication of our latest research article, "Targeted Antibacterial Endolysin to Treat Infectious Wounds on Full-Thickness 3D Skin Model: XZ.700 Efficacy," in the?Pharmaceutics MDPI journal! ? In this study, we present an innovative in vitro 3D model?designed to investigate the crucial processes of?re-epithelialization?and to evaluate the effectiveness of a groundbreaking?anti-adhesive molecule, XZ-700, developed by?Micreos Group. Our findings represent a significant step forward in understanding how to better treat infectious wounds, which pose a considerable challenge in clinical settings. ? Thank you to Bernadette Lombardi, Ph.D. for her invaluable scientific contributions and dedication to this expansive project and a special thank you to?Francesca Rescigno PhD,?our study director, whose expertise has been instrumental in navigating this research journey. ? We are hopeful that this work will pave the way for new therapeutic approaches in wound care and ultimately improve patient outcomes.? We look forward to sharing more updates on our research journey! ? https://lnkd.in/dbppS6rY ? VitroScreen Francesca Rescigno PhD Pharmaceutics MDPI Micreos Group SenzaGen #VitroScreen #PharmaceuticsMDPI #invitro3Dmodel?#reepithelialization?#antiadhesivemolecule #XZ700 #MicreosGroup

The SenzaGen group companies bring together a wide range of expertise within in vitro toxicology and efficacy testing. Here’s an example of important work from VitroScreen, a member of our group. They specialize in testing the effectiveness of chemicals using 3D skin models, and are currently evaluating a new anti-adhesive molecule to help treat infectious wounds. To learn more about this study, you can read their recent publication below. https://lnkd.in/dqbAHK24 #invitro #nonanimal #efficacy